What is PregLem?
Founded in 2006 by Ernest Loumaye and Eric Rolin, PregLem operates as a Swiss-based biopharmaceutical developer focused on innovative therapeutic solutions for women's health. The company distinguishes itself through a deep expertise in clinical product development, regulatory affairs, and commercialization strategies. By leveraging a Scientific Advisory Board composed of leading European academic experts, PregLem has established a credible framework for bringing complex reproductive health treatments to market. Its strategic location near Lake Geneva serves as a hub for its research and development activities, positioning the firm as a key player in the European life sciences sector.
How much funding has PregLem raised?
PregLem has raised a total of $59.9M across 2 funding rounds:
Series A
$26.9M
Series B
$33M
Series A (2007): $26.9M with participation from Sofinnova Partners and MVM Partners
Series B (2007): $33M led by Sofinnova Ventures and MVM Life Science Partner
Key Investors in PregLem
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a focus on building transformative innovations from seed to later-stage.
MVM Partners
An investment firm focused on innovative healthcare companies, supporting businesses that enhance healthcare delivery through quality and cost-effective solutions in medical technology and pharmaceuticals.
What's next for PregLem?
Following its successful capital raising efforts, PregLem has demonstrated the efficacy of its business model, culminating in its acquisition by Gedeon Richter Plc. This strategic exit validates the company's long-term vision of addressing critical gaps in reproductive medicine. Moving forward, the integration into the Richter Group provides the necessary infrastructure to accelerate the commercialization of its pipeline. The firm's history of securing institutional backing serves as a blueprint for how specialized biopharma ventures can leverage targeted investment to achieve significant clinical milestones and ultimately deliver value through successful corporate consolidation.
See full PregLem company page
